Best Practice & Research Clinical Haematology
Volume 20, Issue 2 , Pages 155-170 , June 2007

Risk assessment in haematopoietic stem cell transplantation: Histocompatibility

References 

  1. Horton R, Wilming L, Rand V, et al. Gene map of the extended human MHC. (Review). Nature Reviews. Genetics. 2004;5:889–899
  2. Marsh SG. Nomenclature for factors of the HLA System, update December 2004. Human Immunology. 2005;66:329–330
  3. Parham P, Lomen CE, Lawlor DA, et al. Nature of polymorphism in HLA-A, -B, and -C molecules. Proceedings of the National Academy of Sciences of the United States of America. 1988;85:4005–4009
  4. Begovich AB, McClure GR, Suraj VC, et al. Polymorphism, recombination, and linkage disequilibrium within the HLA class II region. Journal of Immunology (Baltimore, Md.). 1992;148:249–258
  5. Price P, Witt C, Allcock R, et al. The genetic basis for the association of the 8.1 ancestral haplotype (A1, B8, DR3) with multiple immunopathological diseases (Review). Immunological Reviews. 1999;167:257–274
  6. The Sanger Institute; Human Chromosome 6 Project database. http://www.sanger.ac.uk/HGP/Chr6/.
  7. International HapMap Project database. http://www.hapmap.org/.
  8. Mori M, Beatty PG, Graves M, et al. HLA gene and haplotype frequencies in the North American population: the National Marrow Donor Program Donor Registry. Transplantation. 1997;64:1017–1027
  9. Lonjou C, Clayton J, Cambon-Thomsen A, et al. HLA -A, -B, -DR haplotype frequencies in France – implications for recruitment of potential bone marrow donors. Transplantation. 1995;60:375–383
  10. Schipper RF, D'Amaro J, Bakker JT, et al. HLA gene haplotype frequencies in bone marrow donors worldwide registries. Human Immunology. 1997;52:54–71
  11. Tiercy JM, Bujan-Lose M, Chapuis B, et al. Bone marrow transplantation with unrelated donors: what is the probability of identifying an HLA-A/B/Cw/DRB1/B3/B5/DQB1-matched donor?. Bone Marrow Transplantation. 2000;26:437–441
  12. Excoffier L, Slatkin M. Maximum-likelihood estimation of molecular haplotype frequencies in a diploid population. Molecular Biology & Evolution. 1995;12:921–927
  13. Kollman C, Abella E, Baitty RL, et al. Assessment of optimal size and composition of the U.S. National Registry of hematopoietic stem cell donors. Transplantation. 2004;78:89–95
  14. Schreuder GM, Hurley CK, Marsh SG, et al. The HLA Dictionary 2001: a summary of HLA-A, -B, -C, -DRB1/3/4/5 and -DQB1 alleles and their association with serologically defined HLA-A, -B, -C, -DR and -DQ antigens. European Journal of Immunogenetics. 2001;28:565–596
  15. Hurley CK, Baxter-Lowe LA, Begovich AB, et al. The extent of HLA class II allele level disparity in unrelated bone marrow transplantation: analysis of 1259 National Marrow Donor Program donor-recipient pairs. Bone Marrow Transplantation. 2000;25:385–393
  16. Aversa F, Tabilio A, Velardi A, et al. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. The New England Journal of Medicine. 1998;339:1186–1193
  17. Mehta J, Singhal S, Gee AP, et al. Bone marrow transplantation from partially HLA-mismatched family donors for acute leukemia: single-center experience of 201 patients. Bone Marrow Transplantation. 2004;33:389–396
  18. Handgretinger R, Klingebiel T, Lang P, et al. Megadose transplantation of purified peripheral blood CD34(+) progenitor cells from HLA-mismatched parental donors in children. Bone Marrow Transplantation. 2001;27:777–783
  19. O'Reilly RJ, Keever C, Kernan NA, et al. HLA nonidentical T cell depleted marrow transplants: a comparison of results in patients treated for leukemia and severe combined immunodeficiency disease. Transplantation Proceedings. 1987;19:55–60
  20. Soiffer RJ, Mauch P, Fairclough D, et al. CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors. Biology of Blood and Marrow Transplantation. 1997;3:11–17
  21. Henslee-Downey PJ, Abhyankar SH, Parrish RS, et al. Use of partially mismatched related donors extends access to allogeneic marrow transplant. Blood. 1997;89:3864–3872
  22. Gaziev D, Galimberti M, Lucarelli G, et al. Bone marrow transplantation from alternative donors for thalassemia: HLA-phenotypically identical relative and HLA-nonidentical sibling or parent transplants. Bone Marrow Transplantation. 2000;25:815–821
  23. Drobyski WR, Klein J, Flomenberg N, et al. Superior survival associated with transplantation of matched unrelated versus one-antigen-mismatched unrelated or highly human leukocyte antigen-disparate haploidentical family donor marrow grafts for the treatment of hematologic malignancies: establishing a treatment algorithm for recipients of alternative donor grafts. Blood. 2002;99:806–814
  24. Reisner Y, Martelli MF. Bone marrow transplantation across HLA barriers by increasing the number of transplanted cells. (Review). Immunology Today. 1995;16:437–440
  25. Keever-Taylor CA, Bredeson C, Loberiza FR, et al. Analysis of risk factors for the development of GVHD after T cell-depleted allogeneic BMT: effect of HLA disparity, ABO incompatibility, and method of T-cell depletion. Biology of Blood and Marrow Transplantation. 2001;7:620–630
  26. Henslee-Downey PJ, Parrish RS, Macdonald JS, et al. Combined in vitro and in vivo T lymphocyte depletion for the control of graft-versus-host disease following haploidentical marrow transplant. Transplantation. 1996;61:738–745
  27. Kernan NA, Flomenberg N, Dupont B, et al. Graft rejection in recipients of T-cell-depleted HLA-nonidentical marrow transplants for leukemia. Identification of host-derived antidonor allocytotoxic T lymphocytes. Transplantation. 1987;43:842–847
  28. Ho VT, Kim HT, Liney D, et al. HLA-C mismatch is associated with inferior survival after unrelated donor non-myeloablative hematopoietic stem cell transplantation. Bone Marrow Transplantation. 2006;37:845–850
  29. O'Donnell PV, Luznik L, Jones RJ, et al. Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide. Biology of Blood and Marrow Transplantation. 2002;8:377–386
  30. Ottinger HD, Ferencik S, Beelen DW, et al. Hematopoietic stem cell transplantation: contrasting the outcome of transplantations from HLA-identical siblings, partially HLA-mismatched related donors, and HLA-matched unrelated donors. Blood. 2003;102:1131–1137
  31. Beatty PG, Clift RA, Mickelson EM, et al. Marrow transplantation from related donors other than HLA-identical siblings. The New England Journal of Medicine. 1985;313:765–771
  32. Beelen DW, Ottinger HD, Elmaagacli A, et al. Transplantation of filgrastim-mobilized peripheral blood stem cells from HLA-identical sibling or alternative family donors in patients with hematologic malignancies: a prospective comparison on clinical outcome, immune reconstitution, and hematopoietic chimerism. Blood. 1997;90:4725–4735
  33. Anasetti C, Beatty PG, Storb R, et al. Effect of HLA incompatibility on graft-versus-host disease, relapse, and survival after marrow transplantation for patients with leukemia or lymphoma. Human Immunology. 1990;29:79–91
  34. Anasetti C, Amos D, Beatty PG, et al. Effect of HLA compatibility on engraftment of bone marrow transplants in patients with leukemia or lymphoma. The New England Journal of Medicine. 1989;320:197–204
  35. Anasetti C, Hansen JA. Effect of HLA incompatibility in marrow transplantation from unrelated and HLA-mismatched related donors. Transfusion Science. 1994;15:221–230
  36. Caillat-Zucman S, Le Deist F, Haddad E, et al. Impact of HLA matching on outcome of hematopoietic stem cell transplantation in children with inherited diseases: a single-center comparative analysis of genoidentical, haploidentical or unrelated donors. Bone Marrow Transplantation. 2004;33:1089–1095
  37. Bunin N, Aplenc R, Leahey A, et al. Outcomes of transplantation with partial T-cell depletion of matched or mismatched unrelated or partially matched related donor bone marrow in children and adolescents with leukemias. Bone Marrow Transplantation. 2005;35:151–158
  38. Kiehl MG, Kraut L, Schwerdtfeger R, et al. Outcome of allogeneic hematopoietic stem-cell transplantation in adult patients with acute lymphoblastic leukemia: no difference in related compared with unrelated transplant in first complete remission. Journal of Clinical Oncology. 2004;22:2816–2825
  39. National Marrow Donor Program. www.marrow.org.
  40. ASBMT. Guidelines, Policy Statements and Reviews. www.asbmt.org/policystat/policy.html.
  41. Heemskerk MB, van Walraven SM, Cornelissen JJ, et al. How to improve the search for an unrelated haematopoietic stem cell donor. Faster is better than more!. Bone Marrow Transplantation. 2005;35:645–652
  42. van Walraven SM, Heemskerk MB, Lie JL, et al. The importance of identifying a back-up donor for unrelated stem cell transplantation. Bone Marrow Transplantation. 2005;35:437–440
  43. Davies SM, Defor TE, McGlave PB, et al. Equivalent outcomes in patients with chronic myelogenous leukemia after early transplantation of phenotypically matched bone marrow from related or unrelated donors. The American Journal of Medicine. 2001;110:339–346
  44. Hegenbart U, Niederwieser D, Sandmaier BM, et al. Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors. Journal of Clinical Oncology. 2006;24:444–453
  45. Scott I, O'Shea J, Bunce M, et al. Molecular typing shows a high level of HLA class I incompatibility in serologically well matched donor/patient pairs: implications for unrelated bone marrow donor selection. Blood. 1998;92:4864–4871
  46. Ottinger HD, Ferencik S, Beelen DW, et al. Impact of HLA-A,B,C allele mismatches on outcome after unrelated blood stem cell transplantation in whites. Transplantation. 2004;78:1077–1080
  47. Sasazuki T, Juji T, Morishima Y, et al. Effect of matching of class I HLA alleles on clinical outcome after transplantation of hematopoietic stem cells from an unrelated donor. The New England Journal of Medicine. 1998;339:1177–1185
  48. Morishima Y, Sasazuki T, Inoko H, et al. The clinical significance of human leukocyte antigen (HLA) allele compatibility in patients receiving a marrow transplant from serologically HLA-A, HLA-B, and HLA-DR matched unrelated donors. Blood. 2002;99:4200–4206
  49. Petersdorf EW, Gooley TA, Anasetti C, et al. Optimizing outcome after unrelated marrow transplantation by comprehensive matching of HLA class I and II alleles in the donor and recipient. Blood. 1998;92:3515–3520
  50. Flomenberg N, Baxter-Lowe LA, Confer D, et al. Impact of HLA class I and class II high resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplant outcome. Blood. 2004;104:1923–1930
  51. Petersdorf EW, Hansen JA, Martin PJ, et al. Major-histocompatibility-complex class I alleles and antigens in hematopoietic-cell transplantation. The New England Journal of Medicine. 2001;345:1794–1800
  52. Chalandon Y, Tiercy JM, Schanz U, et al. Impact of high-resolution matching in allogeneic unrelated donor stem cell transplantation in Switzerland. Bone Marrow Transplantation. 2006;37:909–916
  53. Carreras E, Jimenez M, Gomez-Garcia V, et al. Donor age and degree of HLA matching have a major impact on the outcome of unrelated donor haematopoietic cell transplantation for chronic myeloid leukaemia. Bone Marrow Transplantation. 2006;37:33–40
  54. Greinix HT, Fae I, Schneider B, et al. Impact of HLA class I high-resolution mismatches on chronic graft-versus-host disease and survival of patients given hematopoietic stem cell grafts from unrelated donors. Bone Marrow Transplantation. 2005;35:57–62
  55. Saarinen-Pihkala UM, Gustafsson G, Ringden O, et al. No disadvantage in outcome of using matched unrelated donors as compared with matched sibling donors for bone marrow transplantation in children with acute lymphoblastic leukemia in second remission. Journal of Clinical Oncology. 2001;19:3406–3414
  56. Gustafsson A, Remberger M, Winiarski J, et al. Unrelated bone marrow transplantation in children: outcome and a comparison with sibling donor grafting. Bone Marrow Transplantation. 2000;25:1059–1065
  57. Hongeng S, Krance RA, Bowman LC, et al. Outcomes of transplantation with matched-sibling and unrelated-donor bone marrow in children with leukaemia. Lancet. 1997;350:767–771
  58. Petersdorf EW, Anasetti C, Martin PJ, et al. Limits of HLA mismatching in unrelated hematopoietic cell transplantation. Blood. 2004;104:2976–2980
  59. Varney MD, Lester S, McCluskey J, et al. Matching for HLA DPA1 and DPB1 alleles in unrelated bone marrow transplantation. Human Immunology. 1999;60:532–538
  60. Petersdorf EW, Gooley T, Malkki M, et al. The biological significance of HLA-DP gene variation in haematopoietic cell transplantation. British Journal of Haematology. 2001;112:988–994
  61. Petersdorf EW, Kollman C, Hurley CK, et al. Effect of HLA class II gene disparity on clinical outcome in unrelated donor hematopoietic cell transplantation for chronic myeloid leukemia: the US National Marrow Donor Program experience. Blood. 2001;98:2922–2929
  62. Loiseau P, Esperou H, Busson M, et al. DPB1 disparities contribute to severe GVHD and reduced patient survival after unrelated donor bone marrow transplantation. Bone Marrow Transplantation. 2002;30:497–502
  63. Shaw BE, Marsh SG, Mayor NP, et al. HLA-DPB1 matching status has significant implications for recipients of unrelated donor stem cell transplants. Blood. 2006;107:1220–1226
  64. van Rood JJ, Loberiza FR, Zhang MJ, et al. Effect of tolerance to noninherited maternal antigens on the occurrence of graft-versus-host disease after bone marrow transplantation from a parent or an HLA-haploidentical sibling. Blood. 2002;99:1572–1577
  65. Tamaki S, Ichinohe T, Matsuo K, et al. Superior survival of blood and marrow stem cell recipients given maternal grafts over recipients given paternal grafts. Bone Marrow Transplantation. 2001;28:375–380
  66. Shimazaki C, Ochiai N, Uchida R, et al. Non-T-cell-depleted HLA haploidentical stem cell transplantation in advanced hematologic malignancies based on the feto-maternal michrochimerism. Blood. 2003;101:3334–3336
  67. Obama K, Utsunomiya A, Takatsuka Y, et al. Reduced-intensity non-T-cell depleted HLA-haploidentical stem cell transplantation for older patients based on the concept of feto-maternal tolerance. Bone Marrow Transplantation. 2004;34:897–899
  68. Shimazaki C, Fuchida S, Ochiai N, et al. Non-T-cell-depleted HLA-haploidentical stem cell transplantation after reduced-intensity conditioning in advanced haematological malignancies based on feto-maternal microchimerism. British Journal of Haematology. 2004;127:474–475
  69. Ferrara GB, Bacigalupo A, Lamparelli T, et al. Bone marrow transplantation from unrelated donors: the impact of mismatches with substitutions at position 116 of the human leukocyte antigen class I heavy chain. Blood. 2001;98:3150–3155
  70. Fleischhauer K, Locatelli F, Zecca M, et al. Graft rejection after unrelated donor hematopoietic stem cell transplantation for thalassemia is associated with nonpermissive HLA-DPB1 disparity in host-versus-graft direction. Blood. 2006;107:2984–2992
  71. Heemskerk MB, Roelen DL, Dankers MK, et al. Allogeneic MHC class I molecules with numerous sequence differences do not elicit a CTL response. Human Immunology. 2005;66:969–976
  72. Petersdorf EW, Gooley T, Malkki M et al. Clinical significance of donor-recipient HLA matching on survival after myeloablative hematopoietic cell transplantation from unrelated donors. Joint report of the IHWG in HCT. Proceedings of the 14th International Histocompatibility Workshop and Conference. Tissue Antigens [in press].
  73. Morishima Y, Takakazu K, Malkki M et al. Effect of HLA-A2 allele disparity on clinical outcome in hematopoietic cell transplantation from unrelated donors. Joint report of the IHWG in HCT. Proceedings of the 14th international Histocompatibility Workshop and Conference. Tissue Antigens [in press].
  74. Atsuta Y, Suzuki R, Yamamoto K, et al. Risk and prognostic factors for Japanese patients with chronic graft-versus-host disease after bone marrow transplantation. Bone Marrow Transplantation. 2006;37:289–296
  75. Mathe G, Amiel JL, Schwarzenberg L, et al. Successful allogeneic bone marrow transplantation in man: chimerism, induced specific tolerance and possible anti-leukemia effects. Blood. 1965;25:179–196
  76. Weiden PL, Sullivan KM, Flournoy N, et al. Antileukemic effect of chronic graft-versus-host disease. Contribution to improved survival after allogeneic marrow transplantation. The New England Journal of Medicine. 1981;304:1529–1533
  77. Kolb HJ, Schattenberg A, Goldman JM, et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood. 1995;86:2041–2050
  78. Horowitz MM, Gale RP, Sondel PM, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood. 1990;75:555–562
  79. Butcher BW, Collins RH. The graft-versus-lymphoma effect: clinical review and future opportunities (Review). Bone Marrow Transplantation. 2005;36:1–17
  80. Spitzer TR, McAfee S, Sackstein R, et al. Intentional induction of mixed chimerism and achievement of antitumor responses after nonmyeloablative conditioning therapy and HLA-matched donor bone marrow transplantation for refractory hematologic malignancies. Biology of Blood and Marrow Transplantation. 2000;6:309–320
  81. Parham P. MHC class I molecules and KIRs in human history, health and survival (Review). Nature Reviews Immunology. 2005;5:201–214
  82. Marsh SG, Parham P, Dupont B, et al. Killer-cell immunoglobulin-like receptor (KIR) nomenclature report, 2002. Immunogenetics. 2003;55:220–226
  83. Hsu KC, Chida S, Geraghty DE, et al. The killer cell immunoglobulin-like receptor (KIR) genomic region: gene-order, haplotypes and allelic polymorphism (Review). Immunological Reviews. 2002;190:40–52
  84. Witt CS, Dewing C, Sayer DC, et al. Population frequencies and putative haplotypes of the killer cell immunoglobulin-like receptor sequences and evidence for recombination. Transplantation. 1999;68:1784–1789
  85. Toneva M, Lepage V, Lafay G, et al. Genomic diversity of natural killer cell receptor genes in three populations. Tissue Antigens. 2001;57:358–362
  86. Valiante NM, Uhrberg M, Shilling HG, et al. Functionally and structurally distinct NK cell receptor repertoires in the peripheral blood of two human donors. Immunity. 1997;7:739–751
  87. Norman PJ, Carrington CV, Byng M, et al. Natural killer cell immunoglobulin-like receptor (KIR) locus profiles in African and South Asian populations. Genes & Immunity. 2002;3:86–95
  88. Denis L, Sivula J, Gourraud PA, et al. Genetic diversity of KIR natural killer cell markers in populations from France, Guadeloupe, Finland, Senegal and Reunion. Tissue Antigens. 2005;66:267–276
  89. Young NT. Immunobiology of natural killer lymphocytes in transplantation (Review). Transplantation. 2004;78:1–6
  90. Ruggeri L, Capanni M, Urbani E, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science. 2002;295:2097–2100
  91. Cook MA, Milligan DW, Fegan CD, et al. The impact of donor KIR and patient HLA-C genotypes on outcome following HLA-identical sibling hematopoietic stem cell transplantation for myeloid leukemia. Blood. 2004;103:1521–1526
  92. Passweg JR, Stern M, Koehl U, et al. Use of natural killer cells in hematopoetic stem cell transplantation (Review). Bone Marrow Transplantation. 2005;35:637–643
  93. Beelen DW, Ottinger HD, Ferencik S, et al. Genotypic inhibitory killer immunoglobulin-like receptor ligand incompatibility enhances the long-term antileukemic effect of unmodified allogeneic hematopoietic stem cell transplantation in patients with myeloid leukemias. Blood. 2005;105:2594–2600
  94. Giebel S, Locatelli F, Lamparelli T, et al. Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. Blood. 2003;102:814–819
  95. Bornhauser M, Schwerdtfeger R, Martin H, et al. Role of KIR ligand incompatibility in hematopoietic stem cell transplantation using unrelated donors. Blood. 2004;103:2860–2861
  96. Bishara A, De Santis D, Witt CC, et al. The beneficial role of inhibitory KIR genes of HLA class I NK epitopes in haploidentically mismatched stem cell allografts may be masked by residual donor-alloreactive T cells causing GVHD. Tissue Antigens. 2004;63:204–211
  97. Davies SM, Ruggieri L, DeFor T, et al. Evaluation of KIR ligand incompatibility in mismatched unrelated donor hematopoietic transplants. Killer immunoglobulin-like receptor. Blood. 2002;100:3825–3827
  98. Hsu KC, Keever-Taylor CA, Wilton A, et al. Improved outcome in HLA-identical sibling hematopoietic stem cell transplantation for acute myelogenous leukemia (AML) predicted by KIR and HLA genotypes. Blood. 2005;105:4878–4884
  99. Schaffer M, Malmberg KJ, Ringden O, et al. Increased infection-related mortality in KIR-ligand-mismatched unrelated allogeneic hematopoietic stem-cell transplantation. Transplantation. 2004;78:1081–1085
  100. Malmberg KJ, Schaffer M, Ringden O, et al. KIR-ligand mismatch in allogeneic hematopoietic stem cell transplantation (Review). Molecular Immunology. 2005;42:531–534
  101. Farag SS, Bacigalupo A, Eapen M, et al. The effect of KIR ligand incompatibility on the outcome of unrelated donor transplantation: a report from the Center for International Blood and Marrow Transplant Research, the European Blood and Marrow Transplant Registry, and the Dutch Registry. Biology of Blood Marrow Transplantation. 2006;12:876–884
  102. Hsu KC, Gooley T, Malkki M, et al. KIR ligands and prediction of relapse after unrelated donor hematopoietic cell transplantation for hematologic malignancy. Biology of Blood Marrow Transplantation. 2006;12:828–836
  103. Sun JY, Gaidulis L, Dagis A, et al. Killer Ig-like receptor (KIR) compatibility plays a role in the prevalence of acute GVHD in unrelated hematopoietic cell transplants for AML. Bone Marrow Transplantation. 2005;36:525–530
  104. International Histocompatibility Working Group. http://www.ihwg.org.
  105. Leung W, Iyengar R, Turner V, et al. Determinants of antileukemia effects of allogeneic NK cells. Journal of Immunology (Baltimore, Md.). 2004;172:644–650
  106. Gagne K, Brizard G, Gueglio B, et al. Relevance of KIR gene polymorphisms in bone marrow transplantation outcome. Human Immunology. 2002;63:271–280

PII: S1521-6926(06)00061-2

doi: 10.1016/j.beha.2006.09.001

Best Practice & Research Clinical Haematology
Volume 20, Issue 2 , Pages 155-170 , June 2007

Article Tools

* Image Usage & Resolution